BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 17680822)

  • 1. Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships.
    El Houda Agueznay N; Badoual C; Hans S; Gey A; Vingert B; Peyrard S; Quintin-Colonna F; Ravel P; Bruneval P; Roncelin S; Lelongt B; Bertoglio J; Fridman WH; Brasnu D; Tartour E
    Clin Exp Immunol; 2007 Oct; 150(1):114-23. PubMed ID: 17680822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma.
    Wang LS; Chow KC; Li WY; Liu CC; Wu YC; Huang MH
    Clin Cancer Res; 2000 Apr; 6(4):1445-51. PubMed ID: 10778976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.
    Kuropkat C; Plehn S; Herz U; Dünne AA; Renz H; Werner JA
    Anticancer Res; 2002; 22(4):2221-7. PubMed ID: 12174907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
    Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood T-lymphocyte and monocyte function and survival in patients with head and neck carcinoma.
    Heimdal JH; Aarstad HJ; Olofsson J
    Laryngoscope; 2000 Mar; 110(3 Pt 1):402-7. PubMed ID: 10718427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
    Riedel F; Götte K; Schwalb J; Hörmann K
    Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant correlation of matrix metalloproteinase and macrophage colony-stimulating factor serum concentrations in patients with head and neck cancer.
    Kuropkat C; Duenne AA; Herz U; Renz H; Werner JA
    Neoplasma; 2004; 51(5):375-8. PubMed ID: 15640942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The soluble interleukin-2 receptor--a marker for squamous cell carcinoma of the upper aerodigestive tract.
    Gottschlich S; Görögh T; Lippert BM; Niemann AM; Folz BJ; Werner JA
    Anticancer Res; 1997; 17(4B):2921-2. PubMed ID: 9329564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
    Bien E; Balcerska A
    Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.
    Bleesing J; Prada A; Siegel DM; Villanueva J; Olson J; Ilowite NT; Brunner HI; Griffin T; Graham TB; Sherry DD; Passo MH; Ramanan AV; Filipovich A; Grom AA
    Arthritis Rheum; 2007 Mar; 56(3):965-71. PubMed ID: 17328073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two distinct stimulus-dependent pathways lead to production of soluble murine interleukin-4 receptor.
    Blum H; Wolf M; Enssle K; Röllinghoff M; Gessner A
    J Immunol; 1996 Sep; 157(5):1846-53. PubMed ID: 8757301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study.
    Tartour E; Deneux L; Mosseri V; Jaulerry C; Brunin F; Point D; Validire P; Dubray B; Fridman WH; Rodriguez J
    Cancer; 1997 Apr; 79(7):1401-8. PubMed ID: 9083163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
    Elg SA; Hill RB; Heldman L; Ramakrishnan S
    Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
    Zwirska-Korczala K; Berdowska A; Jochem J; Sitkiewicz A; Birkner E; Polaniak R; Jedrzejowska-Szypułka H; Korzonek-Szlacheta I
    J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel role of metalloproteinase in cancer-mediated immunosuppression.
    Sheu BC; Hsu SM; Ho HN; Lien HC; Huang SC; Lin RH
    Cancer Res; 2001 Jan; 61(1):237-42. PubMed ID: 11196168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The usefulness of new serum tumor markers in head and neck squamous cell carcinoma.
    Marcos CA; Martínez DA; de Los Toyos JR; Domínguez Iglesias F; Hermsen M; Guervós MA; Pendás JL
    Otolaryngol Head Neck Surg; 2009 Mar; 140(3):375-80. PubMed ID: 19248946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum soluble interleukin 2 receptor in patients with squamous epithelial carcinomas of the upper aerodigestive tract].
    Gottschlich S; Werner JA; Lippert BM; Görögh T; Maune S; Rudert H
    Laryngorhinootologie; 1995 Aug; 74(8):508-11. PubMed ID: 7575904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-18 initiates release of matrix metalloproteinase-9 from peripheral blood mononuclear cells without affecting tissue inhibitor of matrix metalloproteinases-1: suppression by TNF alpha blockage and modulation by IL-10.
    Nold M; Goede A; Eberhardt W; Pfeilschifter J; Mühl H
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):68-75. PubMed ID: 12616343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2.
    Kobayashi H; Tagaya Y; Han ES; Kim IS; Le N; Paik CH; Pastan I; Nelson DL; Waldmann TA; Carrasquillo JA
    Cytokine; 1999 Dec; 11(12):1065-75. PubMed ID: 10623432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma.
    Alhamarneh O; Agada F; Madden L; Stafford N; Greenman J
    Head Neck; 2011 Mar; 33(3):415-23. PubMed ID: 20645289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.